Navigation Links
Antidepressant use during pregnancy may lead to childhood obesity and diabetes
Date:6/21/2014

Hamilton, ON (June 21, 2014) - Women who take antidepressants during pregnancy may be unknowingly predisposing their infants to type 2 diabetes and obesity later in life, according to new research from McMaster University.

The study finds a correlation between the use of the medication fluoxetine during pregnancy and an increased risk of obesity and diabetes in children.

Currently, up to 20 per cent of woman in the United States and approximately seven per cent of Canadian women are prescribed an antidepressant during pregnancy.

"Obesity and Type 2 diabetes in children is on the rise and there is the argument that it is related to lifestyle and availability of high calorie foods and reduced physical activity, but our study has found that maternal antidepressant use may also be a contributing factor to the obesity and diabetes epidemic," said the study's senior investigator Alison Holloway, associate professor of obstetrics and gynecology at McMaster University.

Previous studies have found that pregnant women are particularly vulnerable to depression and it is estimated that up to one in five pregnant women have symptoms of depression during pregnancy.

"While it is known that these drugs can increase the risk of obesity in adults, it is unknown whether a woman's antidepressant use during pregnancy increases the risk of metabolic disturbances in her children," Holloway says, adding the goal of their project was to determine whether maternal exposure to a commonly used antidepressant is related to the development of fatty liver, an outcome commonly seen with obesity, in the offspring.

"We have demonstrated for the first time in an animal model that maternal use of a class of antidepressants called selective serotonin reuptake inhibitors, or SSRIs, resulted in increased fat accumulation and inflammation in the liver of the adult offspring, raising new concerns about the long-term metabolic complications in children born to women who take SSRI antidepressants during pregnancy," says PhD student Nicole De Long, who presented this research on June 22nd at the joint meeting of the International Society of Endocrinology and The Endocrine Society.

Their study does not suggest women should avoid taking antidepressants during pregnancy, only that there may be risks associated with antidepressants that haven't been previously identified, Holloway says.

"The benefit of the study is it may help in the identification of a high-risk group of children who may require specific interventions to prevent obesity and type 2 diabetes later in life," she says.

The next stage of their research will be to understand the mechanistic pathways behind why these drugs pose a risk. "If we can understand how the antidepressant causes adverse metabolic outcomes in the offspring than we can design therapeutic strategies to prevent the damage while allowing women who require these drugs to be treated but reduce the potential harm to the offspring."


'/>"/>

Contact: Veronica McGuire
vmcguir@mcmaster.ca
90-552-591-402-2169
McMaster University
Source:Eurekalert

Related biology news :

1. In utero exposure to antidepressants may influence autism risk
2. Proof that antidepressants and breastfeeding can mix
3. Research produces strong evidence for a new class of antidepressant drugs
4. Antidepressants for bipolar disorder
5. A personal antidepressant for every genome
6. mTOR: A key brain signaling mechanism for rapidly acting antidepressants
7. OHSU Vollum Institute research gives new insight into how antidepressants work in the brain
8. A potential new class of fast-acting antidepressant
9. Biochemical mapping helps explain who will respond to antidepressants
10. A calculator to estimate the likelihood of antidepressant response
11. Do antidepressants impair the ability to extinguish fear?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/11/2017)... NXT-ID, Inc. (NASDAQ:   NXTD ) ("NXT-ID" or ... independent Directors Mr. Robin D. Richards and Mr. ... the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive Officer said," ... and benefiting from their considerable expertise as we move forward ...
(Date:4/4/2017)... NEW YORK , April 4, 2017   ... solutions, today announced that the United States Patent and ... The patent broadly covers the linking of an iris ... the same transaction) and represents the company,s 45 th ... our latest patent is very timely given the multi-modal ...
(Date:3/29/2017)... , March 29, 2017  higi, the health ... in North America , today announced ... and the acquisition of EveryMove. The new investment and ... set of tools to transform population health activities through ... lifestyle data. higi collects and secures data ...
Breaking Biology News(10 mins):
(Date:8/10/2017)... ... August 09, 2017 , ... As a ... reach its ideal customers with the right message. Their effective, cutting-edge inbound marketing ... company, we realize how crucial the agriculture industry is,” said David Phelps, chief ...
(Date:8/10/2017)... ... August 09, 2017 , ... Each year in the United States more than ... live an independent lifestyle and, even worse, the one-year mortality rate is high, ranging ... the University of California Davis Medical Center (Sacramento) and Second Xiangya Hospital of the ...
(Date:8/10/2017)... ... August 10, 2017 , ... DrugDev and the Society ... to demonstrate how Good Clinical Practice (GCP) can be used throughout the site activation ... will discuss the importance of GCP compliance, how sites are affected by GCP during ...
(Date:8/10/2017)... , ... August 10, 2017 , ... ... the AptaFluor SAH Methyltransferase Assay , an enabling new high throughput screening ... pathways that drive cancer and other debilitating diseases. , Chemical modification of gene ...
Breaking Biology Technology: